Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter P.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):10E-5E. doi: 10.1016/j.amjcard.2009.09.014.

PMID:
19895939
2.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
3.

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

Neeli H, Rader DJ.

Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005. Review.

PMID:
18929230
4.

[HDL and CETP in atherogenesis].

Pöss J, Böhm M, Laufs U.

Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Review. German.

PMID:
20082258
5.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

6.

Effects of torcetrapib in patients at high risk for coronary events.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators..

N Engl J Med. 2007 Nov 22;357(21):2109-22. Epub 2007 Nov 5.

7.

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.

Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ.

J Lipid Res. 2007 Jun;48(6):1263-72. Epub 2007 Feb 26.

8.

The hypertension peril: lessons from CETP inhibitors.

Hermann M, Ruschitzka FT.

Curr Hypertens Rep. 2009 Feb;11(1):76-80. Review.

PMID:
19146805
9.

Spotlight on HDL-raising therapies: insights from the torcetrapib trials.

Kontush A, Guérin M, Chapman MJ.

Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):329-36. doi: 10.1038/ncpcardio1191. Epub 2008 Apr 22. Review.

PMID:
18431367
10.

[Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].

Rensen PC, Jukema JW.

Ned Tijdschr Geneeskd. 2008 May 10;152(19):1088-90. Dutch.

PMID:
18552062
11.
12.

Is high HDL cholesterol always good?

Olsson AG.

Ann Med. 2009;41(1):11-8. doi: 10.1080/07853890802609534. Review.

PMID:
19085339
13.

Refocusing on use of cholesteryl ester transfer protein inhibitors.

Kastelein JJ.

Am J Cardiol. 2007 Dec 3;100(11 A):n47-52. Review.

PMID:
18047853
14.
15.

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Shinkai H.

Expert Opin Ther Pat. 2009 Sep;19(9):1229-37. doi: 10.1517/13543770903198451. Review.

PMID:
19663630
16.
17.

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.

Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, Bots ML, Doevendans PA.

Eur Heart J. 2008 Nov;29(22):2792-9. doi: 10.1093/eurheartj/ehn465. Epub 2008 Oct 28.

PMID:
18957472
18.

Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC.

J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23.

PMID:
20332533
19.
20.

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D.

Cardiovasc Res. 2008 Mar 1;77(4):732-9. Epub 2007 Dec 4.

PMID:
18056760

Supplemental Content

Support Center